Oncology

Kara Kelly, MD, chair of pediatrics, Roswell Park Oishei Children's Cancer and Blood Disorders Program, member of the Lymphoma Research Foundation’s Scientific Advisory Board, shares findings on innovative strategies to improve access to new therapies in pediatric cancer.

Sophia Humphreys, PharmD, MHA, BCBBS, a practicing pharmacist and health system director at Sutter Health, discussed the decision-making process for selecting between fixed-duration options and continuous Bruton tyrosine kinase inhibitor (BTKi) therapy for patients with chronic lymphocytic leukemia (CLL).

Insurance hurdles worsen delays, force abandoned treatments, and result in hospitalizations and deaths, radiation oncologists report nationwide.

Our top content from the Spring Association of Cancer Care Centers (ACCC) Annual Meeting & Cancer Center Business Summit featured topics on health care worker retention, advancements in precision medicine, and more!

Sandra Cuellar, PharmD, from the University of Illinois Chicago, highlights the critical role of real-world data in shaping reimbursement models for oncology therapies and emphasizes the growing importance of patient-centered care through shared decision-making, precision medicine, and patient-reported outcomes.

Currently, chemotherapy remains a common treatment for biliary tract cancers, which have a limited survival rate.

Investigators say they may have found a new therapeutic target for patients with double-expressor diffuse large B-cell lymphoma (DLBCL).

Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.

The FDA has granted approval to Azurity Pharmaceuticals' nilotinib tablets (Danziten), a novel version of the tyrosine kinase inhibitor for chronic myeloid leukemia that can be taken without mealtime restrictions.

In this clip from our interview with Oscar B. Lahoud, MD, cochair of our Institute for Value-Based Medicine® evening hosted with NYU Langone Health, he addressed medical mistrust in underrepresented communities.

Care delivery innovations to help patients with cancer avoid emergency department visits are underused. The authors interviewed English- and Spanish-preferring patients at 2 diverse health systems to understand why.

Rituximab-induced interstitial lung disease in patients with non-Hodgkin lymphoma presents with distinct clinical characteristics and bronchoalveolar lavage results.

The American Journal of Managed Care® and Vanderbilt University Medical Center partnered on a recent Institute for Value-Based Medicine® event, which had the theme, “Bringing the Future to the Present in Cancer Care.”

Higher levels of these fatty acids may reduce the risk of developing several types of cancer, though certain risks, such as a potential link to prostate cancer, highlight the complexity of their impact on overall cancer risk.

Despite an overall decline in cancer-specific mortality, death rates from certain cancer types are rising among Asian American and Pacific Islander populations.

Smoking after a cancer diagnosis increases risk of mortality and a second cancer, study finds.

Leveraging Microsoft’s Azure OpenAI, Ontada streamlines oncology data analysis, reducing processing times by 85% to support clinical decisions and improve patient care for over 3000 oncologists across 30 states, according to Wanmei Ou, PhD, vice president of product, data analytics, and artificial intelligence (AI) at Ontada.

At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."

A pioneering program targeting gut microbiome health significantly reduces cancer treatment side effects, enhancing patient well-being and resilience.

Glenn Balasky, executive director of Rocky Mountain Cancer Centers, emphasizes the need for government support to sustain telehealth and suggested a hybrid model combining centralized high-tech care with remote monitoring to address the challenges of providing innovative care in rural settings.

At our recent Institute for Value-Based Medicine® event in Boston, Hari Deshpande, MD, Yale Cancer Center, presented on predictive biomarkers in sarcomas.

Many talks at the Association of Cancer Care Centers (ACCC) 41st National Oncology Conference advocated for the adoption of culturally relevant care, the leveraging of community partnerships, and community engagement to build better trust with patients and improve outcomes.

There are many misconceptions patients might have about clinical trials that prevent them from participating, and it’s important to understand what they are in order to overcome them, said Terry L. Keys, of University of Kentucky Markey Cancer Center.

Naoto T. Ueno, MD, PhD, FACP, of the University of Hawai’I Cancer Center outlines the underrepresentation in clinical trials, the lack of permanent medical oncologists, and issues of trust affecting care for the populations living in Hawaii.

Lalan Wilfong, MD, a 20-year medical oncologist with Texas Oncology, is senior vice president, value-based care, Thyme Care.

The prior authorization process for patients with cancer demonstrates fewer days until submission and lower denial rates for Asian patients relative to White patients.

The theme of our inaugural regional Institute for Value-Based Medicine® event in Boston was, “Elevating Value in Cancer Care,” and one of the 4 panel discussions focused on the important contributions of pharmacists and the practice of pharmacy to the oncology space.